Overview

PulmoSIM Therapeutics is the pharmaceutical subsidiary of VeriSIM Life, developing breakthrough therapies for rare and progressive respiratory diseases to improve patient outcomes and quality of life. Our immediate focus is to address the unmet needs in pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) by targeting the underlying biology to alleviate the need of combination therapies. We leverage BIOiSIM, a first-in-class artificial intelligence bio-simulation platform to accelerate our drug development by bridging the translational gap between preclinical and clinical phases. Currently, we have 2 drug assets in our pipeline for PAH and IPF. We have successfully accomplished the proof-of-concept preclinical studies with key disease-reversal data. We are working hand-in-hand with a world-class strategic advisory board and clinical and manufacturing partners to finish IND-enabling studies to further our developmental roadmap for regulatory approvals. Get in touch if you are interested in learning more about our programs and working with us.